DENTSPLY SIRONA ($XRAY) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of $0.27 per share, missing estimates of $0.28 by $0.01. The company also reported revenue of $961,000,000, beating estimates of $945,623,058 by $15,376,942.
Stock price change since market close: +6.22%
You can see Quiver Quantitative's $XRAY stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
DENTSPLY SIRONA Insider Trading Activity
DENTSPLY SIRONA insiders have traded $XRAY stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $XRAY stock by insiders over the last 6 months:
- GREGORY T LUCIER sold 82,200 shares for an estimated $915,708
- LESLIE F VARON purchased 9,337 shares for an estimated $99,999
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
DENTSPLY SIRONA Hedge Fund Activity
We have seen 153 institutional investors add shares of DENTSPLY SIRONA stock to their portfolio, and 297 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AQR CAPITAL MANAGEMENT LLC removed 7,602,230 shares (-60.8%) from their portfolio in Q4 2025, for an estimated $86,893,488
- ARIEL INVESTMENTS, LLC added 5,274,740 shares (+inf%) to their portfolio in Q4 2025, for an estimated $60,290,278
- DIMENSIONAL FUND ADVISORS LP removed 2,515,798 shares (-48.1%) from their portfolio in Q4 2025, for an estimated $28,755,571
- NORGES BANK removed 2,203,362 shares (-88.1%) from their portfolio in Q4 2025, for an estimated $25,184,427
- MARSHALL WACE, LLP added 2,039,280 shares (+1032.5%) to their portfolio in Q4 2025, for an estimated $23,308,970
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,790,971 shares (-73.9%) from their portfolio in Q4 2025, for an estimated $20,470,798
- ARMISTICE CAPITAL, LLC added 1,562,000 shares (+27.2%) to their portfolio in Q4 2025, for an estimated $17,853,660
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
DENTSPLY SIRONA Government Contracts
We have seen $2,821,190 of award payments to $XRAY over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- DENTAL INFAB: $172,122
- CEREC PRIMESCAN: $171,353
- THIS REQUIREMENT IS FOR THE PURCHASE OF CEREC PRIMESCAN EQUIPMENT AND ACCESSORIES, INEOS X5 (SCANNER, PC & ...: $125,617
- PRIME PRINT SYSTEM: $115,674
- DENTAL CAVITRONS: $100,304
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
DENTSPLY SIRONA Analyst Ratings
Wall Street analysts have issued reports on $XRAY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barrington Research issued a "Outperform" rating on 01/05/2026
To track analyst ratings and price targets for DENTSPLY SIRONA, check out Quiver Quantitative's $XRAY forecast page.
DENTSPLY SIRONA Price Targets
Multiple analysts have issued price targets for $XRAY recently. We have seen 9 analysts offer price targets for $XRAY in the last 6 months, with a median target of $13.0.
Here are some recent targets:
- Michael Cherny from B of A Securities set a target price of $17.0 on 02/19/2026
- Kevin Caliendo from UBS set a target price of $16.0 on 02/03/2026
- Steven Valiquette from Mizuho set a target price of $14.0 on 01/20/2026
- Michael Petusky from Barrington Research set a target price of $14.0 on 01/05/2026
- Jeffrey Johnson from Baird set a target price of $12.0 on 12/16/2025
- Glen Santangelo from Barclays set a target price of $12.0 on 12/09/2025
- Lilia-Celine Lozada from JP Morgan set a target price of $12.0 on 11/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
